Evidence map›Paper›PMID 37988842›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2024

The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.

Adriana Hepner, Judith M Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojaniello, Camille Lea Gerard, Yanina Jl Jansen, Prachi Bhave, Bart Neyns and 18 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 16 institutions in 9 countries.

Adriana HepnerMelanoma Institute Australia, The University of Sydney, NSW, Australia; Instituto do Cancer do Estado de Sao Paulo, SP, Brazil.
Judith M VersluisNetherlands Cancer Institute (NKI), Amsterdam, the Netherlands.
Roslyn WallaceSir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia.
Clara AllayousUniversité Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France.
Lauren Julia BrownCrown Princess Mary Cancer Centre Westmead and Blacktown Hospitals, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Claudia TrojanielloIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Camille Lea GerardPrecision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Yanina Jl JansenDepartment of Thoracic Surgery, University Hospitals Leuven, Leuven 3000, Belgium.
Prachi BhaveSir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; Department of Medical Oncology, Alfred Health, Melbourne, Australia.
Bart NeynsDepartment of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Andrew HaydonDepartment of Medical Oncology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia.
Olivier MichielinPrecision Oncology Center Oncology department, Lausanne University Hospital CHUV, Lausanne, Switzerland.
Joanna ManganaUniversity Hospital Zürich, Zürich, Switzerland.
Oliver KleinOlivia Newton-John Cancer Centre and Austin Health, Melbourne, Australia.
Alexander N ShoushtariMemorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Allison Betof WarnerMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Paolo Antonio AsciertoIstituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
Jennifer Leigh McQuadeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matteo S CarlinoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Lisa ZimmerDepartment of Dermatology, University Hospital Essen, Essen, Germany.
Celeste LebbeUniversité Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, INSERM U976, F-75010 Paris, France.
Douglas B JohnsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville TN, USA.
Shahneen SandhuSir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Australia; University of Melbourne, Melbourne, Australia.
Victoria AtkinsonUniversity of Queensland and Princess Alexandra and Greenslopes Private Hospital, Brisbane, Australia.
Christian U BlankNetherlands Cancer Institute (NKI), Amsterdam, the Netherlands; Leiden University Medical Center (LUMC), Leiden, the Netherlands.
Serigne N LoMelanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Georgina V LongMelanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia.
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, NSW, Australia. Electronic address: alexander.menzies@sydney.edu.au.
The University of Sydney · AUMemorial Sloan Kettering Cancer Center · USThe University of Melbourne · AUInserm · FRIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITAlfred Health · AUEssen University Hospital · DEGreenslopes Private Hospital · AUKU Leuven · BELeiden University Medical Center · NLOlivia Newton-John Cancer Wellness & Research Centre · AUThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · USUniversitair Ziekenhuis Brussel · BEUniversity Hospital of Zurich · CHVanderbilt University Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAnti-PD-1 therapy (PD1) either alone or with anti-CTLA-4 (CTLA4), has high initial response rates, however 20% of patients (pts) with complete response (CR) and 30% with partial response (PR) within 12 months of treatment experience subsequent disease progression by 6 years. The nature and optimal management of this acquired resistance (AR) remains unknown.

methodsPts from 16 centres who responded to PD1-based therapy and who later progressed were examined. Demographics, disease characteristics and subsequent treatments were evaluated.

results299 melanoma pts were identified, median age 64y, 44% BRAFV600m. 172 (58%) received PD1 alone, 114 (38%) PD1/CTLA4 and 13 (4%) PD1 and an investigational drug. 90 (30%) pts had CR, 209 (70%) PR. Median time to AR was 12.6 mo (95% CI, 11.3, 14.2). Most (N = 193, 65%) progressed in a single organ site, and in a solitary lesion (N = 151, 51%). The most frequent sites were lymph nodes (38%) and brain (25%). Management at AR included systemic therapy (ST, 45%), local therapy (LT) +ST (31%), LT alone (21%), or observation (3%). There was no statistical difference in PFS2 or OS based on management, however, PFS2 was numerically superior for pts treated with ST alone who progressed off PD1 therapy than those who progressed on PD1 (2-year PFS2 42% versus 25%, p = 0.249). mOS from AR was 38.0 months (95% CI, 29.5-NR); longer in single-site versus multi-site progression (2-year OS 70% vs 54%, p < 0·001).

conclusionsAcquired resistance to PD1 therapy in melanoma is largely oligometastatic, and pts may have a favorable survival outcome following salvage treatment.

Indexed as

MelanomaAntibodiesCTLA-4 AntigenHumansImmunotherapyMiddle AgedProgrammed Cell Death 1 ReceptorRetrospective StudiesAntibodiesCTLA-4 AntigenPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCytotoxic T-Lymphocyte Antigen 4Disease ProgressionImmunotherapyMelanomaProgrammed death-1Resistance

Identifiers

PMID37988842
PMCPMC11270881
OpenAlexW4388817506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.